🇺🇸 Simivastatin in United States
22 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 20 April 2025 – 20 April 2026
- Total reports: 22
Most-reported reactions
- Headache — 3 reports (13.64%)
- Therapy Cessation — 3 reports (13.64%)
- Arthritis — 2 reports (9.09%)
- Cardiac Disorder — 2 reports (9.09%)
- Cardiac Failure — 2 reports (9.09%)
- Dyspnoea — 2 reports (9.09%)
- Hospitalisation — 2 reports (9.09%)
- International Normalised Ratio Increased — 2 reports (9.09%)
- Nausea — 2 reports (9.09%)
- Unresponsive To Stimuli — 2 reports (9.09%)
Other Other approved in United States
Frequently asked questions
Is Simivastatin approved in United States?
Simivastatin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Simivastatin in United States?
Organon and Co is the originator. The local marketing authorisation holder may differ — check the official source linked above.